sars-cov-2

Documents about sars-cov-2

• COVID-19-Todesfälle in Deutschland#120830DataCite
• COVID-ARE-Konsultationsinzidenz#124807DataCite
• Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)#148548ClinicalTrials.gov
• Clustering of SARS-CoV-2 membrane proteins in lipid bilayer membranes.#159855NCBI PubMed Central
• A Genetically Engineered Biofilm Material for SARS-CoV-2 Capturing and Isolation#223141OpenMETU
• Early Mucosal Type II Interferon Limits SARS-CoV-2 Replication in Humans#241548CaltechDATA
• An unsupervised framework for comparing SARS-CoV-2 protein sequences using LLMs#245292bioRxiv / medRxiv
• Les lésions histologiques pulmonaires associées à l’infection par le Sars-CoV-2#262069HAL (France)
• Phase 2b Booster Vaccination (TURKOVAC) Against COVID-19#435781ClinicalTrials.gov
• Dapagliflozin for Long COVID Syndrome#460032ClinicalTrials.gov
• Landscape of non-SARS-CoV-2 respiratory virus sequence data in Africa#474709bioRxiv / medRxiv
• The Ethics of Human Challenge Trials Using Emerging SARS-CoV-2 Virus Variants#763769PhilArchive
• Role of IL-10 in SARS-CoV-2 Infection During Pregnancy#823249LSU Digital Commons
• Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection#831596ClinicalTrials.gov
• Nigella Sativa in COVID-19#853199ClinicalTrials.gov
• COVID-19 Detection Test in Oncology#859286ClinicalTrials.gov
• COVID-19 Antithrombotic Rivaroxaban Evaluation#877906ClinicalTrials.gov
• Langmuir method data, BAM images, characteristic parameters for liposomes and MD data for amantadine-induced reorganization of model SARS-CoV-2 lipid envelopes.#414535Dane Badawcze UW Dataverse OAI Archive
• Freeze-drying as a Novel Concentrating Method for Wastewater Detection of SARS-CoV-2#18853bioRxiv / medRxiv
• SARS-CoV-2 and the Pandemic Surge in Invasive Group A Streptococcal Disease#29774bioRxiv / medRxiv
• Dynamic properties of an SARS-CoV-2 epidemic model via stochastic PINNs.#30562NCBI PubMed Central
• Genomic and Phylogenetic Dissection of SARS‐CoV‐2 Transmission Networks in Healthcare Workers.#122966NCBI PubMed Central
• Placental Vulnerability to SARS-CoV-2: Viral Entry Pathways and Immune Activation.#140580NCBI PubMed Central
• Statistical crystallography reveals an allosteric network in SARS-CoV-2 M(pro).#152182NCBI PubMed Central
• D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes.#182569NCBI PubMed Central
• COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2#272409ClinicalTrials.gov
• Synthetic Mimotopes of Salivary Peptides against SARS-CoV-2 In Vitro#316385Repositório Institucional Unesp
• Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.#329563ClinicalTrials.gov
• The SARS-CoV-2 RNA interactome#389933S-Space: Seoul National University
• Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001#407771ClinicalTrials.gov
• Complete genome sequence of a novel coronavirus (SARS-CoV-2) isolate from Bangladesh#411692Enlighten Publications
• An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution#415002HAL (France)
• WHO position paper on COVID-19 vaccines, July 2026#419737WHO IRIS
• SARS-CoV-2 Spike Peptides Trigger Nociceptive Responses Through Spinal TLR4 Pathways.#431004NCBI PubMed Central
• The Vietnam Chloroquine Treatment on COVID-19#481780ClinicalTrials.gov
• Maximum Mismatch between Six-Residue Sequences of SARS-CoV-2 Spike Proteins and Human Proteome#643785Harvard DASH
• Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients#802322ClinicalTrials.gov
• Exercise in Child Health#845349ClinicalTrials.gov
• Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine#855112ClinicalTrials.gov
• Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）#864237ClinicalTrials.gov
• Exploring novel kinetics of automated H(2)O(2) nebulization: a breakthrough in SARS-CoV-2 elimination.#156919NCBI PubMed Central
• Honey & Nigella Sativa Trial Against COVID-19#825157ClinicalTrials.gov
• Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine#867881ClinicalTrials.gov
• Supplementary file 1_Favorable safety and immunogenicity of a combined quadrivalent influenza and recombinant SARS-CoV-2 vaccine in Sprague-Dawley rats for both primary and booster immunization.docx#374084Figshare
• Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers#634550Dipòsit Digital de la Universitat de Barcelona
• A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine#839686ClinicalTrials.gov
• TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood#803141ClinicalTrials.gov
• Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic#827797ClinicalTrials.gov
• Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication.#157952NCBI PubMed Central
• Optimizing global genomic surveillance for early detection of emerging SARS-CoV-2 variants.#186171NCBI PubMed Central